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1. Case presentation
The patient was a 71-yr-old man with a primary presentation
of microhematuria. He was a retired pulmonologist but a
current smoker, with a history of 50 pack-years. His cytology
was normal, but cystoscopy revealed multiple lesions. At the
original hospital, a transurethral resection of the bladder
(TURB) without a photodynamic diagnosis (PDD) revealed
pTa low-grade tumors; because there were multiple lesions,
this was a case of intermediate-risk category.
He was given one instillation of mitomycin C (MMC),
followed with 6 mo of MMC maintenance. However, this
regimen caused urgency, with voiding every 20–30 min, up to
10 times per night, necessitating stopping of further
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A 71-yr-old man was transferred to our institution with multiple and recurrent high-
grade pTa bladder cancer 26 mo after an initial presentation of multiple and large pTa
low-grade tumors and concomitant carcinoma in situ, treated with transurethral
resection plus 6-mo postoperative mitomycin C. This case discusses several treat-
ment options in the absence of bacillus Calmette-Guérin (BCG). Immediate radical
cystectomy is an option with excellent survival, since there is a substantial risk of
understaging and disease progression; however, this results in overtreatment in
50% of these patients. Therefore, a conservative approach could be intravesical
combination therapy such as gemcitabine/docetaxel or epirubicin/interferon. In
addition, device-assisted intravesical therapy is becoming an option to consider.
Finally, patients could be included in trials such as immunotherapy trials.
Patient summary: This 71-yr-old patient was diagnosed with recurrent, moder-
ately severe noninvasive bladder tumors, which were removed. The recommended
additional therapy, intravesical bacillus Calmette-Guérin (BCG) instillations, was
not available. Both the pros and the cons of radical surgery (bladder removal) and a
more conservative approach (other intravesical treatments) are discussed.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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intravesical instillations. Cystoscopy at 3 mo after stopping
MMC was normal, but at 6 mo he had two small recurrences,
which were treated with outpatient coagulation. At 20 mo
after his initial presentation, he had another recurrence.
Although cytology was still normal, the tumor appeared more
aggressive on cystoscopy than it had been initially. Another
TURB revealed multiple small pTa lesions, but now of high
grade. The detrusor was free of disease. Owing to his urgency
complaints, no additional intravesical therapy was given. At
26 mo, he had a fourth recurrence and was referred to
Nijmegen.
An outpatient cystoscopy revealed multiple small,
aggressive-looking tumors. TURB confirmed that his tumors
were pTa high grade and more numerous than was noted on
the cystoscopy the month before. His voiding complaints
had essentially resolved, with a capacity of about 300 ml,
and his nocturia decreased to two times per night. For the
sake of this discussion, we will suppose that bacillus
Calmette-Guérin (BCG) is unavailable (as has happened in
recent BCG shortages).
At this point, it is important to consider whether this
represents disease progression. His status has moved from
low grade to high grade, still pTa, but this indeed can be
considered progression based on the definition of the
International Bladder Cancer Group [1]. Since no PDD was
used, random biopsies could have been taken, but since
cytology was normal, not taking biopsies can be defended.
The question is, what should be the next steps regarding
additional therapy? The patient has already had 6 mo of
MMC, so what is next—one instillation of chemotherapy?
Continue with chemotherapy? Start with BCG? What do you
do if no BCG is available?
2. Option A: if BCG is unavailable, radical
cystectomy should be recommended
2.1. Evidence
The first diagnostic question is: what is the risk level of this
patient—high risk or very high risk? Ta high-grade disease
represents 7% of all Ta confined disease [2]. However, the
pathologic diagnosis of Ta or T1 is difficult, and the
likelihood of a diagnostic concordance between the local
and the central pathologists within European Organisation
for Research and Treatment of Cancer (EORTC) studies was
only 23%, which is very low. Ta of high grade is found to be
understaged at cystectomy in one-third of cases [3];
concomitant carcinoma in situ (CIS) is undetected in
>30% of the cases, and of patients with multifocal Ta
high-grade disease, about 8% already have micrometastatic
disease in the lymph nodes at the time of the first diagnosis.
Regarding prognosis, multifocality together with size is a
prognostic factor, and this patient has multifocal disease.
Patients with multifocal Ta high-grade lesions have the
third highest risk of both recurrence (40% in 1 yr) and
progression (5% at 1 yr, but 17% at 5 yr), and the EORTC risk
table shows a concordance with these statistics [3].
According to the European Association for Urology (EAU)
2016 guideline update for non-muscle-invasive bladder
cancer (NMIBC) [4], Ta high-grade disease with multiple
lesions falls into the high-risk category. Primary multifocal Ta
high-grade lesions are at a high risk, but recurrent multifocal
lesions plus CIS are at a higher risk, and the higher-risk
patients are eligible for radical cystectomy, since the presence
of CIS with Ta high-grade lesions will increase the risk of
progression to 17% at 1 yr and 45% at 5 yr. In this patient, CIS
was not looked for, nor were biopsies taken. Therefore, a good
investigation and a correct diagnosis are imperative. TURB
must be complete and adequate, and the use of PDD or
narrow-band imaging is suggested, to improve the diagnosis
of CIS. Metastases can occur prior to muscle invasion through
lymphovascular invasive spread in these patients.
2.1.1. Recommendation
The evidence favors radical cystectomy for this patient in
the absence of BCG, and removal of the lymph nodes at this
stage may be curative. Indeed, radical cystectomy is the best
option for recurrent multifocal Ta high-grade disease after
MMC alone or MMC via electromotive drug administration
(EMDA) or radiofrequency-induced chemohyperthermia
(rf-CHT). In fact, about 20–30% of patients treated with
MMC or EMDA recur after 1 or 3 yr, respectively [5]. A
Cochrane review concluded that EMDA may delay time to
recurrence, but the impact on other endpoints was
uncertain due to study limitations [6]. However, a potential
role was suggested in settings where BCG was not available
(for example).
Disease-specific survival with cystectomy for Ta high-
grade disease ranges from 85% to 90%, and delaying
cystectomy is associated with reduced cancer-specific
survival in these patients. The Denzinger et al’s [7] series
reported that with early cystectomy there is 78% cancer-
specific survival at 10 yr, whereas with delayed cystectomy
there is 51% survival. Oddens et al. [8] reported that at least
one-third of patients receiving doxorubicin, epirubicin, or
MMC have disease recurrence by 1 yr, and the probability of
disease progression is high.
2.2. Conclusion
The argument is for immediate cystectomy for a young
patient with more than five tumors, diameter >3.0 cm, and
concomitant diffuse CIS in the absence of BCG immuno-
therapy. For these patients, an acceptable approach may be
orthotopic neobladder with prostate and seminal sparing,
preserving continence, potency, and probably fertility. For a
recurrent tumor after chemo- or device-assisted therapy,
cystectomy is adequate. Although radical cystectomy is an
overtreatment in 50% of these patients, any initial informed
discussion about treatment of multifocal Ta high-grade
disease in fit patients should include the possibility of
radical cystectomy.
3. Option B: alternative intravesical therapy can be
considered
The question is how to treat a 71-yr-old male, heavy smoker,
with multifocal Ta high-grade disease if BCG is unavailable.
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3.1. Evidence
According to the EORTC risk tables [1], this patient is at an
especially high risk of disease progression, but the
recurrence rate is about the same as for low-grade disease.
This contrasts with the results in the registry at my
institution (Akademiska sjukhuset), where out of 581 of
such patients, the mean recurrence rate was 41%, but
occurrence of progression was 9%. However, this patient has
already had recurrences, so the progression risk will
probably be higher in him.
The patient has already received a course of chemother-
apy with MMC. In our study almost 20 yr ago [9], we found
that BCG was better than MMC for treating CIS, but for
papillary tumors, as in this patient, there was no significant
difference. Therefore, MMC was a good choice for initial
treatment in this patient, but in this case it failed.
Since BCG is not available for this case, we have to look at
other drugs. In a systematic review of six trials with
704 patients [10], three of the trials compared gemcitabine
versus BCG. The efficacy for gemcitabine and BCG in
intermediate-risk patients was similar, but this patient is at
a high risk and gemcitabine was found to be less effective
than BCG in high-risk patients. However, in the absence of
BCG, gemcitabine is at least a promising option, although
more prospective, controlled trials are needed to assess its
efficacy and dosage.
The Finnish Multicentre Study Group [11] and the
FinnBladder VI trial [12] used a combination of epirubicin
and interferon in patients with low-grade Ta or T1 disease.
The former group found a promising effect for the
combination; the latter group found similar benefit for
progression, but for recurrence BCG was significantly more
effective. Likewise in the Nordic bT1 trial [13], randomizing
epirubicin versus BCG, there were more recurrences in the
epirubicin/interferon combination than in the BCG arm, but
30% of the BCG-resistant patients were recurrence free on
the combination after 2 yr; therefore, this would also be an
option, although there were no patients similar to the
present one with Ta tumors in Nordic T1.
Another possibility in the absence of BCG could be a
combination of gemcitabine and either MMC or docetaxel.
This has been tried in a few small trials, with few patients,
usually as salvage therapy after failure of BCG [14]. Little is
known about the long-term efficacy of these combinations;
about a third of the patients seem to be responding after
3 yr, and the toxicity seems acceptable. However, prospec-
tive controlled trials are needed for these combinations.
A Cochrane Database systematic review of EMDA [6]
included only three trials because the quality of all the
others was thought to be too low. The same principal
investigator was a pioneer in this and conducted all three of
the reviewed trials, but the conclusion was that there was
uncertainty regarding serious adverse events and the
quality of the evidence for efficacy could not be properly
estimated. In other words, more rigorous trials are needed
for proper assessment of this approach.
Chemohyperthermia is another device-assisted treat-
ment application. The latest in a series of yearly systematic
reviews looked at 15 publications [15], and found that while
this method is promising, evidence is limited due to a lack of
high-quality randomized trials. Thus, the value of both of
these device-assisted MMC applications is hindered by poor
supporting evidence
Finally, experimental drug delivery systems (eg, Taris, a
device inserted into the bladder where it slowly secretes
chemotherapy, or Urogel, where chemotherapy is released
in a biogel) could be an option in the future, but for now
they are available only for application in controlled trial
settings.
3.2. Conclusion
In conclusion, treatment for this patient is a challenge in
the absence of availability of BCG. Disease progression is a
real problem because this patient has high-grade tumors.
Chemotherapy combinations, such as gemcitabine and
docetaxel, and epirubicin and interferon, have demon-
strated possible efficacy in trials. Of course, these
combinations have not really been shown to be better
than BCG, but in its absence, they can and should be given
careful consideration. Device-assisted intravesical therapy
is becoming a commonly considered option, and quite a
few large trials are ongoing, but more randomized trial
results are needed. There are new immunotherapy options
that have been proved to be successful for advanced
bladder cancers, but trials are needed, and definitive
results are still awaited.
4. Discussion of treatment options
Although Ta high-grade NMIBC is not very frequent and
experience therefore is limited, both the EAU and the
American Urological Association guidelines [4,16] provide
clear therapeutic recommendations: this tumor is consid-
ered to be of high risk, and these patients should be treated
with a re-TURB and maintenance BCG in case of an ongoing
complete response. The only difference is that the
additional benefit of the 2nd and 3rd years of BCG treatment
should be weighed against added costs and inconveniences
according to the EAU guideline.
This leaves a question of what to do if there is no BCG and
there is recurrent high-grade Ta disease, as in this patient. A
conservative approach would mean a high chance of
additional recurrences. In the absence of progression, this
approach is inconvenient for the patient; it will mean
additional resections and more chance of bladder dysfunc-
tion, which although already present was somewhat
improving. From an oncologic point of view, there is little
risk; however, if there is progression, this worsens the
prognosis. Especially if there is progression to muscle-
invasive disease, cancer-specific survival falls dramatically
from around 90% in NMIBC to around 35% after progression
to muscle-invasive disease, and 35% is only half of that of
patients with muscle-invasive disease and no history of
NMIBC [17].
It is of utmost importance to discuss all these factors
and risks with the patients and their families, and to
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include a discussion about the option of radical surgery. If
the conclusion is to proceed with conservative treatment,
MMC remains a viable option. MMC, if used appropriately,
remains an effective drug [18]. Newer and other
chemotherapeutic drugs have been assessed in small
series, such as gemcitabine and taxanes, and combination
chemotherapies using these agents are under investiga-
tion, such as the new class of PD(L)-1 checkpoint
inhibitors. Device-assisted therapies (EMDA and rf-CHT)
need further research. In a randomized controlled trial
with intermediate- and high-risk NMIBC patients, rf-CHT
has been compared with BCG [19]. In the per-protocol
analysis, rf-CHT was found to be safe and effective, with
significantly higher 24-mo recurrence-free survival com-
pared with BCG, although a major limitation of this trial
was premature closure. Another trial [20] did not find a
difference in patients with recurrence following induc-
tion/maintenance BCG, although this trial also had major
limitations, such as patient selection, treatment regi-
mens, and outcome measurement.
If the discussion with the patient concludes with a
decision to go with a more aggressive approach, then
cystectomy is certainly defendable, although as mentioned,
this is a major surgery with morbidity and mortally. An
alternative might be bladder-preserving chemoradiation
[21]. This is contraindicated in cases of concomitant CIS and
hydronephrosis, but without CIS it might be an option in
this man.
5. Final treatment of the case
For the patient in this case, I applied rf-CHT. After six
sessions of MMC 20 mg b.i.d, starting summer 2017, he is
recurrence free until the time of writing (end of 2018) with
maintenance treatment with MMC 20 + 20 mg once every
6 wk, with acceptable bladder function.
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